Mechanism of EGR2 in Allergic Rhinitis
The Regulatory Mechanism of EGR2 Mediated by miR-150-5p on Allergic Rhinitis
1 other identifier
interventional
3
1 country
1
Brief Summary
EGR2 may be a target for the treatment of nasal polyps.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Jan 2023
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2023
CompletedFirst Submitted
Initial submission to the registry
February 7, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 5, 2023
CompletedFebruary 13, 2023
February 1, 2023
2 days
February 7, 2023
February 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
expression of EGR2
expression of EGR2 were analyzed by immunohistochemistry and Western Blot
one months
Study Arms (2)
immunohistochemistry
EXPERIMENTALThirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry
WestBlot
EXPERIMENTALThirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.
Interventions
We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
Eligibility Criteria
You may qualify if:
- All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study.
You may not qualify if:
- Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zu-xia Malead
Study Sites (1)
Department of Central Laboratory of the Third Affiliated Hospital of ZunYi Medical University
Zunyi, 563003, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yong Luo, Doctor
Zunyi Medical College
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 7, 2023
First Posted
February 13, 2023
Study Start
January 30, 2023
Primary Completion
February 1, 2023
Study Completion
May 5, 2023
Last Updated
February 13, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share